ASH 2024 Summary: Full or Reduced Dose Apixaban or Rivaroxaban for E…

2024 ASH Annual Meeting Insights Hub

J. Schaefer

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Updates in Thrombosis and Anticoagulation

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

D. Garcia

Pulmonary Embolism: Role of Catheter-Based Interventions

Baylor College of Medicine

P. Loyalka

Current Treatment Guidelines for ITP: Individualized Therapy and Eme…

Irina Murakhovskaya

CHEST 2024 Insights: Post COVID Cardiac Complications

CHEST Annual Meeting Insights

N. Ramesh

Indy Hematology Review 2025: Classical Hematology - Managing Disorde…

Indy Hematology Review 2025

C. Kessler

Diagnosis of ITP (Including Differential Diagnosis) and Disease Mana…

Drew Provan

ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluat…

Insights from 2025 ASCO® GI Annual Meeting

K. Thein

Thrombophilia Screening: Best Practices and Who Should Be Tested

COR2ED The Heart of Medical Education

S. Middeldorp, J. Connors

Management of Treatment-Naive ITP Patients

Weill Cornell Medicine Oncology & Hematology

J. Bussel

Cancer Associated Thrombosis and Pulmonary Embolism Management

Scripps Health

G. Jay Bishop

The Role of Complement in Disease: Focus on PNH, aHUS, CAPS, and CAD

Ilene Weitz

Recent Advances in Classical Hematology

Indy Hematology Review

R. Brodsky

Key Insights on the FDA Approval of Marstacimab for Hemophilia

Akshat Jain